Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Equivir
- Development stage
- Preclinical
- Lead developer
- ProPhase Labs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Equivir is a blend of polyphenols with demonstrated broad-spectrum antiviral effects. It is intended for use as a health supplement or medication, with an initial focus on over-the-counter offerings for upper respiratory wellness. The technology was developed by Impact BioMedical and licensed to ProPhase Laboratories for worldwide development and commercialization. Equivir is being developed for indications including upper respiratory tract infections, SARS-COV2, Influenza, and Ebola. The dietary supplement version is undergoing clinical studies, with plans for launch in the U.S. in late 2023, while Equivir G is a prescription drug candidate.
- Other names
- Equivir G
02
Targets
ACE2 (Angiotensin-converting enzyme 2)NSP13 (SARS-CoV-2 helicase)Mpro (3C-like proteinase of SARS-CoV-2)Spike-ACE2 PPI (SARS-CoV-2 spike–ACE2 interface)
Beyond the preview
Go deeper on Equivir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Equivir.